The figure is only valid for the sales on the local market, but the company also has export operations.
“Terapia’s core portfolio comprises cardiovascular drugs, antibiotics and over-the-counter products (OTC). The OTCs accounted for 35% of our portfolio and we want them to reach 50% of our portfolio by 2015,” said Dragos Damian, chief executive officer of Terapia Ranbaxy. “Because of the clawback (a tax on sales of drug producers i.e.) we have to pay, more and more producers are shifting to non-prescription drugs.”
The producer ranked ninth on the Romanian market, with a share of 3.7% in April 2011-March 2012. The leaders of the ranking are Sanofi, Roche and Novartis, according to the market research company Cegedim Romania. (EUR1= RON4.4642)
(English version by Loredana Fratila-Cristescu)